With over 25 years’ experience in the pharmaceutical industry, Dr Reed has worked across research, Government and the private sector. At the completion of his melanoma research fellowship in Lausanne, Switzerland, Darryl relocated back to Australia where he joined the Therapeutic Goods Administration (Dept. of Health) and represented the Government on several joint industry committees. Moving to the private sector, Darryl has worked in a variety of senior roles with both Roche and Bayer, spanning regulatory and scientific affairs, medical and clinical support, product development, and sales and marketing.

Dr Reed headed up the Medical teams for Roche and Bayer Consumer Health divisions before moving into dedicated commercial roles. Dr Reed has a 19-year history with Bayer, he has extensive experience in leading strong product portfolios and heading up internal sales teams selling to health care professionals.

Tony is a co-founder of Tissue Repair. He has been actively involved in the Company’s clinical development program, across its two-phase 2B trials, commercialisation strategy, IP, manufacturing, analytical development and overall operations.

Tony holds patents in the company’s proprietary technology platform Glucoprime®.

Tony is an investment banker by background and has extensive experience across early-stage venture assets and in advising technology companies at ANZ Investment Bank and JPMorgan in their respective investment banking teams.

Tony is also a co-founder of Mable Technologies, an online health technology platform operating in the health services and aged care and disability sectors. Mable was named Australian growth technology company of the year in 2020. It was also listed in the Top 10 Deloitte Technology Fast 50 and the AFR Fast 100 list in 2021.

As Tony is a co-founder and has been a Director of Tissue Repair since the Company’s incorporation, he is considered by the Board not to be an independent director.

Dr Namjoshi has over 18 years’ of industry and scientific experience in pharmaceutical development with deep expertise in Chemistry, Manufacturing and Controls (CMC), product development, and global regulatory and quality operations across biologics, small and large molecules, advanced therapeutics, and combination products. Over her career, she has held senior leadership roles in pharmaceutical companies across Australia and has been recognised for guiding novel therapies from early research through clinical development with a strong emphasis on scientific rigor, operational excellence, and regulatory compliance. Dr. Namjoshi has extensive experience interfacing with global regulatory authorities, including the FDA, TGA, EMA, and has successfully led teams through GMP readiness, regulatory submissions, clinical and commercial manufacturing campaigns

Dr. Namjoshi currently serves as Chief Operating Officer at Tissue Repair Ltd where she leads operations spanning product and process development, analytics, manufacturing, regulatory and quality ensuring phase‑appropriate controls and robust technical foundations as the company progresses through its clinical pathway and prepares for global commercialisation.

In addition to her industry role, she also serves on the USP General Chapters-Dosage Forms Expert Committee, where she collaborates with global experts to shape standards that uphold the safety, quality and consistency of medicines worldwide. She is also passionate about mentoring emerging scientific leaders and contributes actively to the broader scientific and innovation community through industry collaborations and her role as an IMNIS mentor.

Dion  Cohen  is  a  Chartered  Accountant  with  over  15  years  of  experience  in  senior  finance  roles.  He  has worked  across  both listed  and  unlistedsectors  with  a  focus  on  financial  reporting,  governance,  capital management, and establishing streamlined finance functions to support growth.

Anhthu leads Global Clinical Operations at Tissue Repair, bringing years of experience across pharmaceuticals, healthcare AI technology and medical devices.

A seasoned clinical operations executive, Anhthu has held key senior leadership roles at several biopharma companies. As Executive Director of Clinical Operations at 9 Meters Biopharma, she led programs focused on gastrointestinal and rare diseases. Prior to that, she served as Senior Director of Clinical Development at Synergy Biopharma, recognized for playing a key role in the NDA and sNDA of plecanatide. At AbbVie, she made significant contributions to the sNDA of cariprazine.

Anhthu’s experience includes supporting both 510(k) clearances and Premarket Approval (PMA) supplement for the Tissue Technologies division while at Integra Life Sciences.

Beyond her work in clinical development, Anhthu has founded and worked across various AI-driven healthcare initiatives. She has also advised various startups implementing AI and digital health technologies and served on Rutgers University’s Big Data Advisory Board.

Patrick Kania is a medical device executive and brings over 20 years commercialisation and leadership experience in Medical Devices, Pharma, and Health Technologies, within sales and marketing management, and general management, working across the US, Europe and APAC.

Mr Kania’s commercial experience spans large public organisations and early stage start-ups. Patryk is CEO and President USA, and Managing Director of Field Orthopaedics Ltd. He has previously held senior roles at Smith+Nephew, Abbott, J&J Medical and Roche. Patryk’s knowledge of global market access, licensing arrangements, and commercialisation of medical devices will be invaluable to the Company in co-shaping its clinical, regulatory and commercial strategy. Patryk also currently serves as non-executive director of EMVision Medical Devices Ltd (ASX:EMV).

Alistair McKeough is a lawyer who also has extensive experience as a director of private and listed corporations in many sectors, including professional services, corporate services, regulatory technology, sports technology, charities, education and biotech. He was formerly Head of Professional Services at Automic Group, where he led the legal and company secretarial teams. Mr McKeough is currently a non-executive director of Recce Pharmaceuticals Ltd (ASX:RCE). Mr McKeough will serve as Chair of TRP’s board.

Dr Kelly was the inventor of Tissue Repair’s technology 28-year background in medical research, principally in transplantation immunology and cancer research. As Head of the Transplantation Laboratories of the Department of Surgery, The University of Sydney, Dr Kelly led a research team investigating the issue of impaired wound healing in immunosuppressed transplant recipients. That work led to the finding that yeast-derived, micro-particulate β- (1-3)(1-6) glucan optimally restores normal rates of healing in incisional wounds in animals where the repair process is inhibited by immunosuppressive therapy.  Dr Kelly currently is CEO of Noxopharm limited a cancer drug development company, and acts as a Scientific Advisor to TR Therapeutics. He has been awarded an Adjunct Professorship by the University of Sydney.

Dr Kelly indirectly holds shares through an entity that he controls.

Dr. Goldman is Founder and Medical Director of Goldman Butterwick Fitzpatrick, Groff & Fabi, Cosmetic Laser Dermatology. A graduate of Boston University, Summa Cum Laude, and the Stanford University Medical School, Dr. Goldman is a Volunteer Clinical Professor in Medicine/Dermatology at the University of California, San Diego. Dr Goldman is Board Certified by both the American Board of Dermatology and the American Board of Cosmetic Surgery.
He is a fellow of the American Academy of Dermatology, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, American Academy of Cosmetic Surgery and the American Society of Liposuction Surgery. He is former President of the American College of Phlebology and President-Elect of the American Society for Dermatologic Surgery, He presently serves on the Board of Trustees for the American Academy of Cosmetic Surgery. He has authored and/or co-authored 21 Textbooks on Dermatology, Sclerotherapy, Ambulatory Phlebectomy, Cutaneous Laser Surgery, Cellulite and Dermatologic Surgery as well as over 300 peer-reviewed publications and textbook chapters.
Dr. Goldman is a recent recipient of the American Academy of Cosmetic Surgery’s 21st Century Achievement Award and the 2009 President’s Award from the American Society for Dermatologic Surgery for Outstanding Contribution in Teaching and Research. He also serves as a medical consultant to numerous companies, including Obagi Medical, SkinMedica, Allergan Medical, Merz Cosmetic, Medicis Pharmaceuticals, Lumenis Laser Corporation, New Star Lasers, and many others.

Dr. Kirsner is Professor, Chairman, and the endowed Harvey Blank Chair in the Dr. Phillip Frost Dermatology in the Department of Dermatology and Cutaneous Surgery and Professor of Public Health Sciences at the University of Miami Miller School of Medicine. He is Chief of Dermatology at the University of Miami Hospital and Clinics and Jackson Memorial Hospital and directs the University of Miami Hospital Wound Center. Dr. Kirsner received his undergraduate degree from Texas A&M University, his medical degree from the University of Miami and a PhD in epidemiology from the University of Miami, after he completed his clinical training. His clinical training included internal medicine, a clinical and research fellowship in wound healing and dermatology at the University of Miami. His research interests include Wound Healing and Skin Cancer Epidemiology. Dr. Kirsner serves as one of 3 academic editors for the journal Wound Repair and Regeneration and on the editorial boards for several other journals in dermatology and wound healing.  Dr. Kirsner serves in national leadership positions in both Wound Healing and Dermatology, including being immediate Vice President of the American Academy of Dermatology and serving as Vice President of the Wound Healing (he will President in 2026).  In addition to career development awards, foundation, industry sponsored funding and CDC funding, he currently leads or is part of several NIH funded grants. Independent of books, book chapters and abstracts, he has published over 600 articles.

Dr Woodward is an expert in wound management, rehabilitation, geriatric medicine, dementia and cognitive disorders and quality use of medications. He is currently Director of Aged Care Research and heads the Wound Clinic at one of Melbourne’s large metropolitan teaching hospitals. He is past President of the Australian Wound Management Association, past Editor of Wound Practice and Research and of the Geriatric Therapeutics section of the Journal of Pharmacy Practice and Research.

Vaclav Vetvicka, Ph.D., is a Professor of Pathology at the Department of Pathology of the University of Louisville in Louisville, Kentucky, USA. He graduated from Charles University in Prague, Czech Republic with an advanced degree in biology and obtained his Ph.D. from the Czechoslovak Academy of Sciences. His postgraduate training included a stay at the Oklahoma Medical Research Foundation, Oklahoma City, OK, and at the Institute of Microbiology, Prague, Czech Republic.

His main area of research interest focuses on the development of natural immunomodulators. In addition to the glucan research, Dr. Vetvicka helped to launch glucan in several countries including USA, France, Brazil, Turkey, South Korea, Australia and Czech Republic.
Dr. Vetvicka is author and co-author of more than 360 peer-reviewed publications, ten books and nine international patents. In addition, he presented over 80 invited lectures at the universities and research institutes all around the world.